Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint (for specialized target groups only)

Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failure
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news